VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/21/2025 12:04 PDT] VolitionRx Limited (NYSE:VNRX), Up By 100% ($0.68) From $0.68 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [07/21/2025 12:04 PDT] VolitionRx Limited (NYSE:VNRX), Up By 100% ($0.66) From $0.661 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [07/21/2025 07:11 PDT] VNRX Expected to Trade Up After Bullish Patterns Develop
• [07/10/2025 07:15 PDT] VNRX Expected to Trade Up After Bullish Patterns Develop
• [07/09/2025 07:31 PDT] VNRX Expected to Trade Down After Bearish Patterns Develop
• [06/20/2025 15:33 PDT] VolitionRx Limited (NYSE:VNRX), Up By 100% ($0.65) From $0.65 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/18/2025 07:20 PDT] VNRX, Expected to Trade Higher After Bullish Insider Trading
• [06/04/2025 12:42 PDT] VolitionRx Limited (NYSE:VNRX), Up By 100% ($0.51) From $0.51 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/22/2025 07:25 PDT] VNRX Expected to Trade Up After Bullish Patterns Develop